Bumma, N., Richter, J., Brayer, J., Zonder, J. A., Dhodapkar, M., Shah, M. R., Hoffman, J. E., Mawad, R., Maly, J. J., Lentzsch, S., Suvannasankha, A., Roy, P., Dey, J., Chokshi, D., Boyapati, A., Visich, J., Houvras, Y., Rodriguez Lorenc, K., Kroog, G. S., & Jagannath, S. (2022). Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study. Blood, 140(Supplement 1), 10140–10141. https://doi.org/10.1182/blood-2022-159969
Subjects:
Diagnosis and Treatment of Multiple Myeloma
(OpenAlex Topic)
Therapeutic Antibodies: Development, Engineering, and Applications
(OpenAlex Topic)
Role of Fibroblast Activation in Cancer Progression
(OpenAlex Topic)
Publication Type:
Article
Unique ID:
10.1182/blood-2022-159969
Journal:
Publication Date:
Data Source:
OpenAlex
Source Link: